Rapid7, Inc.

RPD

$11.47

+3.61%

2026-09-03 16:00:00 EDT+$0.40

Technology

Software - Infrastructure

NASDAQ

Active Trading

Rapid7, Inc. specializes in delivering cutting-edge cybersecurity solutions. Central to its offerings is a sophisticated, cloud-native platform designed to equip organizations with ...

Recent News of RPD

GlobeNewsWire7/28/2026Neutral

Rapid7 Becomes First Major Security Operations Platform to Unite SecOps and GRC

BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today announced the general availability of Rapid7 Cyber GRC, expanding the Rapid7 Command Platform with native governance, risk, and compliance (GRC) capabilities. The new offering helps organizations continuously understand cyber risk, validate control effectiveness, and simplify compliance by connecting GRC workflows with live security operations data.

InvestorPlace7/26/2026Neutral

5 Takeover Targets for the AI Revolution

Tom Yeung here with your Sunday Digest . In the 2010s, getting acquired was the ultimate startup status symbol.

GlobeNewsWire7/14/2026Neutral

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today announced that the company will release its second quarter 2026 financial results on Monday, August 10, 2026, after the financial markets close. The company will host a conference call that same day to discuss its results and business outlook at 4:30 p.m.

GuruFocus7/13/2026Neutral

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy ag

Business Wire7/13/2026Neutral

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicot.

Rapid7, Inc.

Recent News of RPD

Rapid7 Becomes First Major Security Operations Platform to Unite SecOps and GRC

5 Takeover Targets for the AI Revolution

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Rapid7 Becomes First Major Security Operations Platform to Unite SecOps and GRC

5 Takeover Targets for the AI Revolution

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Rapid7 (RPD) Moves 7.6% Higher: Will This Strength Last?

Reveal Expands European Offerings with Private Deployment, AI-Powered Review and Logikcull's Government Transparency Solutions

Rapid7 Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rapid7: New CEO And AI Opportunities Draw Attention

Rapid7 Appoints Wael Mohamed Chief Executive Officer; Corey Thomas to Become Executive Chairman

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

Rapid7 Q1 2026 Threat Landscape Report Finds Vulnerability Exploitation Overtakes Social Engineering as the Top Initial Access Vector

Rapid7, Inc. (RPD) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

RAPID7 LAUNCHES CYBER GRC EARLY ACCESS PROGRAM WITH 360 ADVANCED TO BRIDGE SECURITY OPERATIONS AND COMPLIANCE FOR ORGANIZATIONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

Rapid7 Launches Cyber Governance, Risk, and Compliance (GRC) Early Access Program to Unify Security Data, Risk Context, and Compliance Workflows

5 Cybersecurity Stocks That May Be Acquired in 2026's M&A Wave

Rapid7 to Participate in Upcoming Investor Conferences

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

Rapid7, Inc. (RPD) Q1 2026 Earnings Call Transcript

Rapid7 (RPD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Rapid7 (RPD) Q1 Earnings and Revenues Beat Estimates

Rapid7 Announces First Quarter 2026 Financial Results

Supply Chain of RPD

Upstream

Downstream

Proxies

Recent News of RPD

Rapid7 Becomes First Major Security Operations Platform to Unite SecOps and GRC

5 Takeover Targets for the AI Revolution

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Rapid7 Becomes First Major Security Operations Platform to Unite SecOps and GRC

5 Takeover Targets for the AI Revolution

Rapid7 to Report Second Quarter 2026 Financial Results on August 10

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)

Rapid7 (RPD) Moves 7.6% Higher: Will This Strength Last?

Reveal Expands European Offerings with Private Deployment, AI-Powered Review and Logikcull's Government Transparency Solutions

Rapid7 Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Rapid7: New CEO And AI Opportunities Draw Attention

Rapid7 Appoints Wael Mohamed Chief Executive Officer; Corey Thomas to Become Executive Chairman

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

Rapid7 Q1 2026 Threat Landscape Report Finds Vulnerability Exploitation Overtakes Social Engineering as the Top Initial Access Vector

Rapid7, Inc. (RPD) Presents at J.P. Morgan 54th Annual Global Technology, Media and Communications Conference Transcript

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

RAPID7 LAUNCHES CYBER GRC EARLY ACCESS PROGRAM WITH 360 ADVANCED TO BRIDGE SECURITY OPERATIONS AND COMPLIANCE FOR ORGANIZATIONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

Rapid7 Launches Cyber Governance, Risk, and Compliance (GRC) Early Access Program to Unify Security Data, Risk Context, and Compliance Workflows

5 Cybersecurity Stocks That May Be Acquired in 2026's M&A Wave

Rapid7 to Participate in Upcoming Investor Conferences

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD

Rapid7, Inc. (RPD) Q1 2026 Earnings Call Transcript

Rapid7 (RPD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Rapid7 (RPD) Q1 Earnings and Revenues Beat Estimates

Rapid7 Announces First Quarter 2026 Financial Results

Supply Chain of RPD

Upstream

Downstream

Proxies